TNB-738
Solid Tumors
Key Facts
About Tenacia Biotechnology
Clinical-stage biotech developing small molecule therapies for oncology and immunology using proprietary drug discovery platforms.
View full company profileAbout Ancora Bio
Ancora Biotech is a strategic holding entity formed by former executives and investors of Teneobio to advance a portfolio of three multi-specific antibody programs. Its most advanced asset, TNB-486 (anti-CD19xCD3), is in Phase 1 for B-cell malignancies, while two preclinical programs target CD38 for metabolic diseases and HBVxCD3 for a functional cure of chronic hepatitis B. The company's model involves spinning out assets into dedicated subsidiaries (TeneoTwo, TeneoFour, TeneoTen) while centralizing oversight of manufacturing and clinical development. Key financial backers include Lightspeed Venture Partners and Sutter Hill Ventures.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| DM001 | Domabio | Phase 1 |
| DM002 | Domabio | Phase 1 |
| DM005 | Domabio | Phase 1 |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| CAR-T Solid Tumor Program | Carina Biotech | Phase 1/2a |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |